biote Corp. Class A (BTMD)

Biote Corp.'s stock price has declined by 46.72% from September 24, 2024, to September 23, 2025. Key events include a 4.7% increase in total revenue in Q1 2025 driven by dietary supplements, surpassing EPS expectations but missing revenue estimates in Q2 2025, a strategic organizational restructuring leading to lowered 2025 guidance, insider purchases by Guines LLC and the CEO and directors, and the negative impact of a software transition on procedure revenue growth in Q4 2024 and Q1 2025.

While the hormone balancing therapy market is generally not highly seasonal, Biote Corp. has indicated some seasonality in its operations. The company's total revenue growth for the first half of 2024 was expected to be impacted by the timing of seasonal promotions, and the timing of Biote's annual marketing event shifted from the second quarter to the third quarter in 2025.

Biote Corp. operates as a practice-building business in the hormone optimization and therapeutic wellness sector, focusing on training physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy. The company offers the "Biote Method," a comprehensive platform with education, training, certification, practice management, and inventory management software. Biote also sells dietary supplements and sterile pellet insertion kits.

Biote Corp. is headquartered in Irving, Texas, United States, and has a significant presence across the United States with over 8,600 medical providers, while also expanding internationally.

Biote Corp.'s brand reputation has been influenced by its science-based approach and the launch of its BioteRx wellness platform. Operational disruptions from the transition to new clinical decision support software, ongoing legal proceedings, and a material weakness in internal controls have presented challenges.

Biote Corp. has a substantial institutional ownership base, with 215 institutional owners and shareholders holding 18,594,134 shares, including major owners like 325 Capital Llc, Bandera Partners LLC, BlackRock, Inc., and Vanguard Group Inc. Guines LLC made a significant purchase of 856,609 shares in March 2025.